2. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69 –74. 3. Yarchoan M, Johnson BA 3rd, Lutz E R, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 2017;17: 209 –22.4. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-speci ﬁc, therapeutic vaccines for cancer. Nat Rev Immunol 2018;18:168 –82. 5. Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 2021;18:215 –29. 6. Sasso E, D ’Alise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A. New viral vectors for infectious diseases and cancer. Semin Immunol 2020;50:101430. 7. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors thatD’Alise et al. Clin Cancer Res; 30(11) June 1, 2024 CLINICAL CANCER RESEARCH 2422Downloaded from http://aacrjournals.org/clincancerres/article-pdf/30/11/2412/3454679/2412.pdf by guest on 10 December 2024 primes, boosts, and sustains functional HCV-speci ﬁc T cell memory. Sci Transl Med 2014;6:261ra153.